{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-068534","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.443973+00:00","generated_at":"2026-05-22T00:39:18.339856+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexeo Therapeutics reports Q1 net loss $32.7M, cash $106.9M; LX2006 data positive","bullets":["Net loss of $32.7M ($0.99 per share) vs $21.7M ($0.77) in Q1 2024; R&D expense $17.2M, G&A $16.6M.","Cash, cash equivalents and investments of $106.9M expected to fund operations into 2027.","LX2006 in FA cardiomyopathy: interim data show 25% mean LVMI reduction and 115% avg frataxin increase; registrational study planned by early 2026.","LX2020 (PKP2-ACM): Cohort 1 showed 71% and 115% PKP2 increases; enrolling cohort 3; interim update expected H2 2025.","Redeployed $20M from non-cardiac pipeline; limited reduction in force of ~15% employees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-068534","json":"https://secwatch.observer/filing/0000950170-25-068534.json","markdown":"https://secwatch.observer/filing/0000950170-25-068534.md","text":"https://secwatch.observer/filing/0000950170-25-068534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/0000950170-25-068534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/lxeo-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:39:18.339856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}